Compare Cronos Group Inc (CRON) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Levi Strauss & Co. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Levi Strauss & Co. trades at $19.01 (market cap $7.51B). The key difference: Levi Strauss & Co. is far larger — about 6.3× Cronos Group Inc's market cap, and Levi Strauss & Co. pays a 3.28% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Levi Strauss & Co. for 70 Days on average.
| CRON | LEVI | |
|---|---|---|
Market Cap | $1.20B | $7.51B |
Volume | 450,387 | 17,462,954 |
Sector | Health | Consumer Cyclical |
52-Week High | $3.55 | $25.53 |
52-Week Low | $2.30 | $17.92 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $401.73M | $9.06B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
Levi Strauss (LEVI) trades at $19.05, down 7.21% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.84, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a '90s fashion revival benefiting the brand and the appointment of a new CFO effective November 2026. Cash flow trends have improved, with net cash flow turning positive in 2025 after prior volatility.
The outlook is positive given analyst consensus of a $27.80 price target and 79% buy ratings, though near-term price weakness and competitive pressures in apparel present risks. Earnings growth and direct-to-consumer expansion are key catalysts, but investors face execution risks and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
